Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2006-07-11
Original market date: [1]	1973-12-31
Product name:	DALACIN C PHOSPHATE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	00260436
Product Monograph/Veterinary Labelling:	**Date:** 2022-01-10 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	PFIZER CANADA ULC 17300 Trans-Canada Highway Kirkland Quebec Canada H9J 2M5
Class:	Human
Dosage form(s):	Solution
Route(s) of administration:	Intravenous , Intramuscular
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	08:12.28.20

Anatomical Therapeutic Chemical (ATC): [4] J01FF01 CLINDAMYCIN

Active ingredient group (AIG) number: [5] 0105830002

List of active ingredient(s)

Active ingredient(s) [8]	Strength
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)	150 MG / ML

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2020-10-27
Original market date: [1]	2020-10-27
Product name:	DAPTOMYCIN FOR INJECTION

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02490838
Product Monograph/Veterinary Labelling:	**Date:** 2020-07-21 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	SANDOZ CANADA INCORPORATED 110 Rue De Lauzon Boucherville Quebec Canada J4B 1E6
Class:	Human
Dosage form(s):	Powder For Solution
Route(s) of administration:	Intravenous
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	08:12.28.12

Anatomical Therapeutic Chemical (ATC): [4] J01XX09 DAPTOMYCIN

Active ingredient group (AIG) number: [5] 0152298001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
DAPTOMYCIN	500 MG / VIAL

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2005-09-15
Original market date: [1]	2002-01-09
Product name:	DILTIAZEM HYDROCHLORIDE INJECTION

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02244728
Product Monograph/Veterinary Labelling:	**Date:** 2005-08-10 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	SANDOZ CANADA INCORPORATED 110 Rue De Lauzon Boucherville Quebec Canada J4B 1E6
Class:	Human
Dosage form(s):	Solution
Route(s) of administration:	Intravenous
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	24:28.92

Anatomical Therapeutic Chemical (ATC): [4]	C08DB01 DILTIAZEM
Active ingredient group (AIG) number: [5]	0115863003

List of active ingredient(s)

Active ingredient(s) [8]	Strength
DILTIAZEM HYDROCHLORIDE	5 MG / ML

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2016-07-13
Original market date: [1]	1997-01-30
Product name:	ENTOCORT

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02229293
Product Monograph/Veterinary Labelling:	**Date:** 2023-03-09 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	TILLOTTS PHARMA GMBH Warmbacher Strasse 80 Rheinfelden Baden-Wuerttemberg Germany 79618
Class:	Human
Dosage form(s):	Capsule (Sustained-Release)
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	68:04.00

Anatomical Therapeutic Chemical (ATC): [4]	A07EA06 BUDESONIDE
Active ingredient group (AIG) number: [5]	0116807006

List of active ingredient(s)

Active ingredient(s) [8]	Strength
BUDESONIDE	3 MG

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2017-12-15
Original market date: [1]	2006-05-08
Product name:	APO-FLECAINIDE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02275546
Product Monograph/Veterinary Labelling:	**Date:** 2017-11-07 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	APOTEX INC 150 Signet Drive Toronto Ontario Canada M9L 1T9
Class:	Human
Dosage form(s):	Tablet
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	24:04.04.12

Anatomical Therapeutic Chemical (ATC): [4] C01BC04 FLECAINIDE

Active ingredient group (AIG) number: [5] 0116696001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
FLECAINIDE ACETATE	100 MG

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada / Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2019-05-30
Original market date: [1]	1980-12-31
Product name:	FLUORESCITE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	00505005
Product Monograph/Veterinary Labelling:	**Date:** 2020-12-29 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	ALCON CANADA INC 2665 Meadowpine Blvd Mississauga Ontario Canada L5N 8C7
Class:	Human
Dosage form(s):	Solution
Route(s) of administration:	Intravenous
Number of active ingredient(s):	1
Schedule(s):	Ethical
American Hospital Formulary Service (AHFS): [3]	36:58.00

Anatomical Therapeutic Chemical (ATC): [4] V04CX OTHER DIAGNOSTIC AGENTS

Active ingredient group (AIG) number: [5] 0160251001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
FLUORESCEIN (FLUORESCEIN SODIUM)	10 % / W/V

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2020-01-02
Original market date: [1]	1958-12-31
Product name:	FUNGIZONE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	00029149
Product Monograph/Veterinary Labelling:	**Date:** 2019-12-12 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	CHEPLAPHARM ARZNEIMITTEL GMBH Ziegelhof 24 Greifswald Mecklenburg - West Pomerania Germany 17489
Class:	Human
Dosage form(s):	Powder For Solution
Route(s) of administration:	Intravenous
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	08:14.28

Anatomical Therapeutic Chemical (ATC): [4] J02AA01 AMPHOTERICIN B

Active ingredient group (AIG) number: [5] 0105864001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
AMPHOTERICIN B	50 MG / VIAL

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada / Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2022-10-14
Original market date: [1]	1994-12-31
Product name:	HUMATIN

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02078759
Product Monograph/Veterinary Labelling:	**Date:** 2022-11-23 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	SEARCHLIGHT PHARMA INC 1600 Rue Notre Dame Ouest, Suite 312 Montreal Quebec Canada H3J 1M1
Class:	Human
Dosage form(s):	Capsule
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	08:30.04

Anatomical Therapeutic Chemical (ATC): [4] A07AA06 PAROMOMYCIN

Active ingredient group (AIG) number: [5] 0125807001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
PAROMOMYCIN (PAROMOMYCIN SULFATE)	250 MG

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2019-03-28
Original market date: [1]	1986-12-31
Product name:	HYDROXYZINE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	00646024
Product Monograph/Veterinary Labelling:	**Date:** 2023-10-12 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	AA PHARMA INC UNIT 1 1165 Creditstone Road Vaughan Ontario Canada L4K 4N7
Class:	Human
Dosage form(s):	Capsule
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	28:24.92

Anatomical Therapeutic Chemical (ATC): [4] N05BB01 HYDROXYZINE

Active ingredient group (AIG) number: [5] 0106172002

List of active ingredient(s)

Active ingredient(s) [8]	Strength
HYDROXYZINE HYDROCHLORIDE	25 MG

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada / Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2015-09-25
Original market date: [1]	1997-11-14
Product name:	ISOFLURANE USP

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02231929
Product Monograph/Veterinary Labelling:	**Date:** 2018-05-23 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	FRESENIUS KABI CANADA LTD 165 Galaxy Blvd, Suite 100 Toronto Ontario Canada M9W 0C8
Class:	Human
Dosage form(s):	Liquid
Route(s) of administration:	Inhalation
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	28:04.16

Anatomical Therapeutic Chemical (ATC): [4] N01AB06 ISOFLURANE

Active ingredient group (AIG) number: [5] 0114368001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
ISOFLURANE	99.9 %

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada / Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2008-05-07
Original market date: [1]	1997-08-20
Product name:	LASIX SPECIAL

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02224755
Product Monograph/Veterinary Labelling:	**Date:** 2022-10-24 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	SANOFI-AVENTIS CANADA INC 1755 Steeles Avenue West Toronto Ontario Canada M2R 3T4
Class:	Human
Dosage form(s):	Tablet
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	40:28.08

Anatomical Therapeutic Chemical (ATC): [4] C03CA01 FUROSEMIDE

Active ingredient group (AIG) number: [5] 0101944006

List of active ingredient(s)

Active ingredient(s) [8]	Strength
FUROSEMIDE	500 MG

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2021-01-18
Original market date: [1]	2014-12-01
Product name:	OTEZLA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02434334
Product Monograph/Veterinary Labelling:	**Date:** 2020-08-05 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	AMGEN CANADA INC 300 6775 Financial Drive Mississauga Ontario Canada L5N 0A4
Class:	Human
Dosage form(s):	Tablet
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	92:36.00

Anatomical Therapeutic Chemical (ATC): [4] L04AA32 APREMILAST

Active ingredient group (AIG) number: [5] 0156231002

List of active ingredient(s)

Active ingredient(s) [8]	Strength
APREMILAST	30 MG

Risk Management Plans [7]

A Risk Management Plan (RMP) for this product was submitted.

Pharmacovigilance/Monitoring Activity
Registry

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

7 Refer to the Health Canada Guidance Documents - "Submission of Risk Management Plans and Follow-up Commitments" as well as "Submission of targeted Risk Management Plans Follow-up Commitments for Prescription Opioid-containing Products" for additional details.

8	An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Application information

Search tips
Drug product database terminology
Drug product database data extracts

Related information

MedEffect Canada
Adverse drug reaction - veterinary drugs
Notice of compliance database
Licensed natural health products database

Contact us

Content support
Technical support

Version 4.0.3

Date modified: 2024-08-14

Government of Canada / Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2024-02-26
Original market date: [1]	2024-02-26
Product name:	RANOPTO
Description:	SINGLE USE VIAL

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02542250
Product Monograph/Veterinary Labelling:	**Date:** 2023-10-11 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	TEVA CANADA LIMITED 30 Novopharm Court Toronto Ontario Canada M1B 2K9
Class:	Human
Dosage form(s):	Solution
Route(s) of administration:	Intravitreal
Number of active ingredient(s):	1
Schedule(s):	Schedule D , Prescription
Biosimilar Biologic Drug:	Yes

American Hospital Formulary Service (AHFS): [3]	52:92.00
Anatomical Therapeutic Chemical (ATC): [4]	S01LA04 RANIBIZUMAB
Active ingredient group (AIG) number: [5]	0152224001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
RANIBIZUMAB	10 MG / ML

Risk Management Plans [7]

A Risk Management Plan (RMP) for this product was submitted.

Additional Risk Minimization Measures
Patient Education

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

7 Refer to the Health Canada Guidance Documents - "Submission of Risk Management Plans and Follow-up Commitments" as well as "Submission of targeted Risk Management Plans Follow-up Commitments for Prescription Opioid-containing Products" for additional details.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Application information

Search tips
Drug product database terminology
Drug product database data extracts

Related information

MedEffect Canada
Adverse drug reaction - veterinary drugs
Notice of compliance database
Licensed natural health products database

Contact us

Content support
Technical support

Version 4.0.3

Date modified: 2024-08-14

Government of Canada / Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2023-06-26
Original market date: [1]	2023-06-26
Product name:	SULFAMETHOXAZOLE AND TRIMETHOPRIM FOR INJECTION, USP

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02525917
Product Monograph/Veterinary Labelling:	**Date:** 2023-12-18 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	AURO PHARMA INC 3700 Steeles Avenue West, Suite 402 Woodbridge Ontario Canada L4L 8K8
Class:	Human
Dosage form(s):	Solution
Route(s) of administration:	Intravenous
Number of active ingredient(s):	2
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	08:12.20

Anatomical Therapeutic Chemical (ATC): [4]	J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM
Active ingredient group (AIG) number: [5]	0208901005

List of active ingredient(s)

Active ingredient(s) [8]	Strength
SULFAMETHOXAZOLE	80 MG / ML
TRIMETHOPRIM	16 MG / ML

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2018-08-02
Original market date: [1]	1984-12-31
Product name:	TOBREX

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	00614254
Product Monograph/Veterinary Labelling:	**Date:** 2020-02-12 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	NOVARTIS PHARMACEUTICALS CANADA INC 100 700 Rue Saint-Hubert Montreal Quebec Canada H2Y 0C1
Class:	Human
Dosage form(s):	Ointment
Route(s) of administration:	Ophthalmic
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	52:04.04

Anatomical Therapeutic Chemical (ATC): [4] S01AA12 TOBRAMYCIN

Active ingredient group (AIG) number: [5] 0110230005

List of active ingredient(s)

Active ingredient(s) [8]	Strength
TOBRAMYCIN	0.3 % / W/W

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada / Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2015-04-10
Original market date: [1]	2015-04-10
Product name:	AURO-VALGANCICLOVIR

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02435179
Product Monograph/Veterinary Labelling:	**Date:** 2018-03-14 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	AURO PHARMA INC 3700 Steeles Avenue West, Suite 402 Woodbridge Ontario Canada L4L 8K8
Class:	Human
Dosage form(s):	Tablet
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	08:18.32

Anatomical Therapeutic Chemical (ATC): [4] J05AB14 VALGANCICLOVIR

Active ingredient group (AIG) number: [5] 0147203001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
VALGANCICLOVIR (VALGANCICLOVIR HYDROCHLORIDE)	450 MG

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2019-04-02
Original market date: [1]	1989-12-31
Product name:	VANCOCIN

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	00788716
Product Monograph/Veterinary Labelling:	**Date:** 2024-02-14 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	SEARCHLIGHT PHARMA INC 1600 Rue Notre Dame Ouest, Suite 312 Montreal Quebec Canada H3J 1M1
Class:	Human
Dosage form(s):	Capsule
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	08:12.28.16

Anatomical Therapeutic Chemical (ATC): [4] A07AA09 VANCOMYCIN

Active ingredient group (AIG) number: [5] 0131315006

List of active ingredient(s)

Active ingredient(s) [8]	Strength
VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE)	250 MG

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Government of Canada Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2020-03-09
Original market date: [1]	2020-03-09
Product name:	VELTASSA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02481359
Product Monograph/Veterinary Labelling:	**Date:** 2024-04-05 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD Rechenstrasse 37 St Gallen St Gallen Switzerland 9014
Class:	Human
Dosage form(s):	Powder For Suspension
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	40:18.18

Anatomical Therapeutic Chemical (ATC): [4] V03AE09 PATIROMER CALCIUM

Active ingredient group (AIG) number: [5] 0160711001

List of active ingredient(s)

Active ingredient(s) [8]	Strength
PATIROMER (PATIROMER SORBITEX CALCIUM)	8.4 G / SACHET

Risk Management Plans [7]

A Risk Management Plan (RMP) for this product was submitted.

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

7 Refer to the Health Canada Guidance Documents - "Submission of Risk Management Plans and Follow-up Commitments" as well as "Submission of targeted Risk Management Plans Follow-up Commitments for Prescription Opioid-containing Products" for additional details.

8	An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi

Application information

Search tips
Drug product database terminology
Drug product database data extracts

Related information

MedEffect Canada
Adverse drug reaction - veterinary drugs
Notice of compliance database
Licensed natural health products database

Contact us

Content support
Technical support

Version 4.0.3

Date modified: 2024-08-14

Government of Canada / Gouvernement du Canada

Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:	**Marketed**
Current status date:	2014-04-02
Original market date: [1]	2014-04-02
Product name:	SANDOZ VORICONAZOLE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT files, can be obtained in the alternate format help section.

DIN:	02399253
Product Monograph/Veterinary Labelling:	**Date:** 2024-02-15 Product monograph/Veterinary Labelling (PDF version ~ 175
Company:	SANDOZ CANADA INCORPORATED 110 Rue De Lauzon Boucherville Quebec Canada J4B 1E6
Class:	Human
Dosage form(s):	Tablet
Route(s) of administration:	Oral
Number of active ingredient(s):	1
Schedule(s):	Prescription
American Hospital Formulary Service (AHFS): [3]	08:14.08

Anatomical Therapeutic Chemical (ATC): [4]	J02AC03 VORICONAZOLE
Active ingredient group (AIG) number: [5]	0150242002

List of active ingredient(s)

Active ingredient(s) [8]	Strength
VORICONAZOLE	200 MG

New search Same active ingredient group number

Footnotes

1 The earliest marketed date recorded in the Drug Product Database.

3 The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. *AHFS® Pharmacologic/Therapeutic Classification©* used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Informatior ASHP is not responsible for the accuracy of transpositions from the original context.

4 The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

5 The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

- the first portion (2 digits) identifies the number of active ingredients,
- the second portion (5 digits) identifies the unique groups of active ingredients(s),
- the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of -2% to +10%.

8 An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The followir link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me fi